Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24299444 | 0.94 | CRBN (0.54) | CRBNDDB1PDK2GPR119ALDH1A1 | |
| SCHEMBL24481058 | 0.93 | CRBN (0.48) | CRBNDDB1PDK2GPR119 | |
| SCHEMBL20046318 | 0.92 | CRBN (0.54) | CRBNDDB1PDK2GPR119ALDH1A1 | |
| SCHEMBL22291548 | 0.91 | CRBN (0.46) | CRBNDDB1PDK2GPR119ALDH1A1 | |
| SCHEMBL22951135 | 0.91 | CRBN (0.48) | CRBNDDB1PDK2GPR119 | |
| SCHEMBL25502269 | 0.88 | CRBN (0.43) | CRBNDDB1PDK2ALDH1A1 | |
| SCHEMBL22291619 | 0.86 | DDB1 (0.55) | CRBNDDB1MAPT | |
| SCHEMBL20046178 | 0.85 | CRBN (0.51) | CRBNDDB1PDK2MAPT | |
| SCHEMBL20046596 | 0.85 | CRBN (0.51) | CRBNDDB1PDK2MAPT | |
| SCHEMBL22951134 | 0.85 | CRBN (0.47) | CRBNDDB1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| WO-2022048605-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATIONS | 南昌奥瑞药业有限公司 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | CRBN 576/4885DDB1 1692/4885PDK2 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.